PIPELINE
Our Programs
Our research and therapeutic pipeline are driven by a commitment to addressing the unmet needs of patients affected by central nervous system (CNS) disorders, neurodegenerative diseases, and rare diseases. These are areas where effective treatments are currently lacking, and where patients are in desperate need of innovative solutions.
| Program | Target Indication | Drug Type | Discovery | Preclinical | Clinical | Collaboration Partners |
|
|---|---|---|---|---|---|---|---|
| BMD-001 | Alzheimer’s disease (AD) | BDDSTM – ASO (miR-485-3p Antagomir) |  |
||||
| Amyotrophic Lateral Sclerosis (ALS) | BDDSTM – ASO (miR-485-3p Antagomir) | |
|||||
| Parkinson’s disease (PD) | BDDSTM – ASO (miR-485-3p Antagomir) | |
|||||
| BMD-0131 | Frontotemporal Dementia (FTD) | BDDSTM – siRNA (Undisclosed) |  |
||||
| BMD-0231 | PD & Synucleinopathies | BDDSTM – siRNA (Undisclosed) | |
||||
| BMD-0311 | Epilepsy | BDDSTM – ASO (Undisclosed) |  |
||||
| BMD-0431 | Glaucoma | BDDSTM – RNAi (Undisclosed) |  |
||||
| BIOK-0031 | CNS disease | BDDSTM – siRNA (Undisclosed) | |
||||
| BIOK-0221 | CNS disease | BDDSTM – ASO (Undisclosed) | |
||||
BDDSTM = Brain Targeting Drug Delivery System
ALS = Amyotrophic lateral sclerosis
Stay Connected
